• Trinity Biotech held its annual general meeting on Sept. 30, 2026, with shareholders backing all items put to a vote.
• Grant Thornton’s appointment as statutory auditor was approved, covering service through the next annual general meeting when accounts are presented.
• The board received authority to set the statutory auditor’s remuneration; the filing does not confirm any fee decision has been made.
• Shareholders also approved the re-appointment of Dr Andrew Omidvar as a director; the filing does not address any subsequent board actions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001554855-26-002068), on October 05, 2026, and is solely responsible for the information contained therein.